NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
Clinical Trials
12 trialsNCT02782468 2023-11-03
A Study of Pevonedistat in Adult East Asian Participants
Takeda
Phase 1 Completed
NCT03330106 2023-03-28
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT03486314 2022-04-18
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT01814826 2020-03-03
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
Takeda
Phase 1 Completed
NCT03057366 2019-11-18
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00911066 2013-12-05
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00722488 2013-11-18
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00677170 2013-07-16
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT01011530 2013-07-16
Dose Escalation Study of MLN4924 in Adults With Melanoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed